Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Washington

Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Washington keessatti

Qorannoo 84 Kansara Qara'a Non-Small Cell f Washington keessatti hirmaatuu jiru.

Magaalota Washington keessatti

Takkalaa qorannoo (Ingiliffa)

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Valley Medical Center /ID# 253950, Renton

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT04928846

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Medical Oncology Associates - Spokane /ID# 277172, Spokane
Northwest Medical Specialties Tacoma /ID# 270534, Tacoma

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06568939

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Fred Hutchinson Cancer Center. /ID# 277939, Seattle
Northwest Cancer Specialists - Vancouver /ID# 277855, Vancouver

Namoota walitti qabaa jiraSadarkaa 2/3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07155187

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Vista Oncology - East Olympia /ID# 275438, Olympia
Northwest Medical Specialties Tacoma /ID# 270469, Tacoma

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06772623

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Valley Medical Center, Renton

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT04267848

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

University of Washington, Fred Hutchinson Cancer Center, Seattle

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Swedish Cancer Institute ( Site 0143), Seattle
St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192), Silverdale

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06623422

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Northwest Medical Specialties - Gig Harbor, Gig Harbor
Northwest Medical Specialties - Puyallup Medical Oncology, Puyallup
Northwest Medical Specialties - Tacoma, Tacoma

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06472245

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Swedish Cancer Institute-Edmonds, Edmonds
Swedish Cancer Institute-Issaquah, Issaquah
Swedish Medical Center-First Hill, Seattle

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06498635

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Fred Hutchinson Cancer Center, Seattle

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06625775

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Local Institution - 0384, Spokane

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

University of Washington - Fred Hutchinson Cancer Center, Seattle
Compass Oncology, Vancouver

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT06765109

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Swedish Cancer Institute, Seattle

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05498428

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

American Oncology Network Vista Oncology Division-West office, Olympia
American Oncology Network Vista Oncology Division-East office, Olympia

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07144280

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Fred Hutchinson Cancer Center, Seattle

Namoota walitti qabaa jiraQorannoo ilaalaa

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT04981119

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Vista Oncology Inc PS, Olympia

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT05920356

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Aberdeen
Research Site, Renton

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06868277

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Northwest Cancer Specialists, P.C., Vancouver

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07222566

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Vista Oncology, Olympia
Summit Cancer Centers, Spokane

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06667076

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

American Oncology Network Vista Oncology Division-West office, Olympia
American Oncology Network Vista Oncology Division-East office, Olympia

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06758401

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Northwest Medical Specialties, Tacoma

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06047379

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Fred Hutchinson Cancer Center, Seattle
University of Washington Medical Center - Montlake, Seattle

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Swedish Cancer Institute - Edmonds, Edmonds
Swedish Medical Center, Seattle
Cancer Care Northwest - Vercler, Spokane Valley
fi 1 dabalataa

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06890598

Pan-tumor MRD Study

Northwest Medical Specialties (NWMS), Tacoma

Namoota walitti qabaa jiraQorannoo ilaalaa

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06605404

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Tacoma
Research Site, Vancouver
Research Site, Wenatchee

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06357533

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Swedish Medical Center, Seattle

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06618287

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Edmonds
Research Site, Seattle

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 hanga 95 · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT05061550

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0515, Edmonds
Local Institution - 0499, Lacey
Local Institution - 0508, Seattle

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06561386

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

University of Washington Fred Hutchinson Cancer Center, Seattle

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06814496

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

University of Washington Fred Hutchinson, Seattle

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT05983432

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Olympia
Research Site, Seattle
Research Site, Spokane
fi 1 dabalataa

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT06692738

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Fred Hutchison Cancer Center, Seattle

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT06855771

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Seattle
Clinical Study Site, Vancouver

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT06767514

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Fred Hutchinson Cancer Research Center, Seattle

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver

Namoota walitti qabaa jiraSadarkaa 2/3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT04613596

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Summit Cancer Treatment Center, Spokane

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT06899126

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Vista Oncology - East Olympia /ID# 262303, Olympia

Namoota walitti qabaa jiraSadarkaa 2/3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06236438

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Providence Sacred Heart Medical Center, Spokane

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06303505

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

University of Washington (Data Collection Only), Seattle

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT04410796

A Study of KK2269 in Adult Participants With Solid Tumors

University of Washington, Seattle

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06266299

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.